Zacks: Analysts Expect Myovant Sciences Ltd (NYSE:MYOV) to Announce -$0.81 EPS

Equities research analysts expect Myovant Sciences Ltd (NYSE:MYOV) to announce earnings per share of ($0.81) for the current quarter, Zacks reports. Zero analysts have made estimates for Myovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.77) and the lowest estimate coming in at ($0.84). Myovant Sciences reported earnings per share of ($1.04) in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.1%. The business is expected to announce its next earnings results on Thursday, February 6th.

On average, analysts expect that Myovant Sciences will report full year earnings of ($3.29) per share for the current fiscal year, with EPS estimates ranging from ($3.35) to ($3.18). For the next financial year, analysts forecast that the business will report earnings of ($3.16) per share, with EPS estimates ranging from ($3.72) to ($2.51). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.07).

A number of brokerages have commented on MYOV. Zacks Investment Research downgraded Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 9th. Svb Leerink began coverage on Myovant Sciences in a research note on Monday, August 19th. They set an “outperform” rating and a $26.00 price target for the company. Leerink Swann began coverage on Myovant Sciences in a report on Monday, August 19th. They set an “outperform” rating and a $26.00 price target for the company. ValuEngine lowered Myovant Sciences from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $20.00 price target (up previously from $18.00) on shares of Myovant Sciences in a research note on Tuesday, November 19th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $23.46.

In other Myovant Sciences news, major shareholder Sciences Ltd. Roivant acquired 3,500,000 shares of Myovant Sciences stock in a transaction that occurred on Monday, November 25th. The stock was acquired at an average price of $15.00 per share, with a total value of $52,500,000.00. Following the purchase, the insider now owns 44,509,411 shares in the company, valued at $667,641,165. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders purchased 3,876,099 shares of company stock valued at $58,656,406. 3.00% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of MYOV. Barclays PLC lifted its holdings in Myovant Sciences by 24.6% in the 3rd quarter. Barclays PLC now owns 11,317 shares of the company’s stock worth $59,000 after purchasing an additional 2,234 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Myovant Sciences by 46.3% during the third quarter. Tower Research Capital LLC TRC now owns 9,741 shares of the company’s stock worth $51,000 after purchasing an additional 3,083 shares during the period. Atria Investments LLC boosted its position in Myovant Sciences by 87.9% during the second quarter. Atria Investments LLC now owns 22,915 shares of the company’s stock worth $162,000 after purchasing an additional 10,720 shares during the period. Northern Trust Corp acquired a new position in Myovant Sciences during the second quarter valued at approximately $105,000. Finally, BlackRock Inc. grew its holdings in Myovant Sciences by 59.1% during the second quarter. BlackRock Inc. now owns 44,637 shares of the company’s stock valued at $404,000 after purchasing an additional 16,580 shares during the last quarter. 38.81% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:MYOV traded down $0.17 during midday trading on Friday, hitting $16.61. 2,183,809 shares of the stock were exchanged, compared to its average volume of 787,760. The company has a market capitalization of $1.67 billion, a PE ratio of -4.06 and a beta of 2.02. Myovant Sciences has a 52-week low of $4.14 and a 52-week high of $26.02. The company has a debt-to-equity ratio of 5.88, a quick ratio of 2.79 and a current ratio of 2.79. The business’s fifty day simple moving average is $9.18 and its two-hundred day simple moving average is $8.24.

About Myovant Sciences

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Article: Shanghai Stock Exchange Composite Index

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.